1. Home
  2. YCBD vs ACXP Comparison

YCBD vs ACXP Comparison

Compare YCBD & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo cbdMD Inc.

YCBD

cbdMD Inc.

HOLD

Current Price

$0.69

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.60

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YCBD
ACXP
Founded
2015
2017
Country
United States
United States
Employees
42
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
8.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
YCBD
ACXP
Price
$0.69
$1.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$2.00
$95.50
AVG Volume (30 Days)
148.8K
74.5K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.70
N/A
Revenue Next Year
$7.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.29
52 Week High
$2.56
$8.34

Technical Indicators

Market Signals
Indicator
YCBD
ACXP
Relative Strength Index (RSI) 40.82 33.49
Support Level $0.62 $1.37
Resistance Level $0.84 $2.26
Average True Range (ATR) 0.04 0.12
MACD -0.00 0.01
Stochastic Oscillator 14.65 12.50

Price Performance

Historical Comparison
YCBD
ACXP

About YCBD cbdMD Inc.

cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: